RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Tranzyme Pharma announced today that the US Food and Drug Administration (FDA) completed its review of the Company’s Investigational New Drug (IND) application for TZP-102, Tranzyme’s second drug candidate to reach clinical development.
